2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Ottawa, ON, Canada (UroToday.com) The toxicity of Pb212-NNV003 (an anti-CD37 antibody from Nordic Nanovector) was first evaluated in tumor-free mice. No hemotoxicity was observed except for a slight reduction in platelets, which recovered. Next mice were injected with either lymphoma (Daudi) or leukemia (MC2) cells. Pb212-NNV003 was injected at a single dose of 10,15, or 20 microCi.

There was a significant increase in median survival at all doses compared to controls of saline, cold NNV002, or Pb212Cetuximabb. At the respective doses 70%, 90% and 100% of mice injected with MEC-2 cells were tumor-free 20 weeks post cell injection compared with a median survival of 4.9, 5.4 and 9.3 weeks in the control samples. Similar results were obtained with the Daudi cells.


Presented by: Amal Saidi, PhD, Orano Med, Plano, Texas, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada